EnGene Holdings Inc. (ENGN), a clinical-stage genetic medicines company, announced on Wednesday that its Chief Executive Officer, Jason Hanson intends to resign from his role upon the appointment of a successor.
Hanson has cited personal and health reasons for his decision to leave the company.
EnGene has initiated a hunt for a new CEO and retained a leading executive search firm.
For comments and feedback: editorial@rttnews.com